The behavior of cancer cells, which could not be obtained conventionally, can now be obtained non-invasively and in real-time.
AntiCancer Inc. first reported the stable introduction of green fluorescent protein (GFP) into CHO-K1 cells in 1997 (Chishima et al, Cancer Res. 1997). This report served as a starting point, leading to the creation of many cancer cells that express various fluorescent proteins (GFP/RFP), which are utilized in research on cancer cell proliferation, migration, invasion, and metastasis, as well as in studies on the interactions between normal cells and cancer cells. 【Latest Research, Development, and Services】 - Fluorescent protein-expressing cancer cells - Fluorescently labeled nude mice - Fluorescent imaging systems - Contract research services - Other services For more details, please contact us or download the catalog.
Inquire About This Product
basic information
【Research Results】 - Real-time observation of cancer cell proliferation and regression, and monitoring of the therapeutic effects of anticancer drugs through whole-body imaging. - Correlation between tumor area and tumor volume. - Time course of angiogenesis. - Interaction between tumors and host cells. - Movement of cancer cells within lymphatic vessels and blood vessels. - Real-time cell cycle analysis. - Subcellular imaging using Dual Color Cells. For more details, please contact us or download the catalog.
Price information
Please contact us.
Delivery Time
※Please contact us.
Applications/Examples of results
For more details, please contact us or download the catalog.
catalog（1）
Download All Catalogs
Company information
AntiCancer Inc., headquartered in the United States, was founded in 1984 in San Diego, California, by Robert M. Hoffman, a professor at the University of California, San Diego School of Medicine. It is a biotech venture focused on the research, development, and sales of anticancer drugs and diagnostic agents. Considering the future potential of the biotechnology and pharmaceutical market in Japan, AntiCancer Japan Co., Ltd. was established on November 27, 2006. In April 2007, a P2 level research facility was constructed in Ibaraki City, Osaka Prefecture. A lab was opened for the research and development of in vivo imaging using its proprietary technology, which includes fluorescent proteins (green fluorescent protein (GFP) and red fluorescent protein (RFP)), as well as the exhibition of small animal models. Currently, the company primarily supports cancer research for its clients using fluorescent imaging technology.